NasdaqCM:NGENPharmaceuticals
Assessing NervGen Pharma (NasdaqCM:NGEN) Valuation After Its $60 Million Follow On Equity Offering
NervGen Pharma (NGEN) has drawn fresh attention after completing a follow on public equity offering of approximately $60 million, including common shares and warrants, to fund its neuroreparative drug development programs.
See our latest analysis for NervGen Pharma.
The follow on offering has coincided with sharp share price pressure, with NervGen Pharma’s 1 day share price return down 43.48% and its year to date share price return down 64.63%. This comes even though the 5 year total...